FDA Approves Gradual Dosing for Alzheimer’s Drug

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly’s Alzheimer’s drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous type of brain swelling, the company said on Wednesday. Kisunla, given as a…

Read Full Article (External Site)